Summary from ASCO 2020 virtual meeting
This article nicely summarises the most exciting research highlights from [...]
ASCO 2020: Lenvatinib plus pembrolizumab for disease progression after immunotherapy for metastatic kidney cancer
Results from a phase II trial of a combination of [...]
ASCO 2020: Subtypes of kidney cancer differ in sites of metastases
A paper presented during the 2020 American Society of Clinical [...]
ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC
Results from a phase II study of bevacizumab and erlotinib [...]
ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab
Two studies were presented during the 2020 American Society of [...]
ASCO 2020: Biomarkers for immunotherapy treatment for advanced kidney cancer
Biomarkers enable doctors predict which patients will respond to which [...]
ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer
Results from a phase II international trial led by researchers [...]
ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy
A study presented during the 2020 American Society of Clinical [...]
ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
